Bloomberg Talks: Novo Nordisk President and CEO Talks Wegovy Pill

Date: December 23, 2025
Host: Katie Greifeld (Bloomberg)
Guest: Mike Dostar, President and CEO of Novo Nordisk

Episode Overview

This episode features a timely and revealing interview with Mike Dostar, President and CEO of Novo Nordisk, following the FDA approval of the oral (pill) version of their blockbuster obesity drug Wegovy. The discussion centers on the significance of this breakthrough, Novo Nordisk’s competitive strategy, supply and distribution plans, market expansion, pricing, and future ambitions. Dostar shares insights on how this first-to-market pill could reshape obesity treatment, address patient hesitancy, and expand opportunities for both the company and patients worldwide.

Key Discussion Points & Insights

1. First-to-Market Advantage and Product Efficacy

(00:34 - 01:21)

• Dostar expresses excitement about being first to launch an oral GLP-1 for obesity in the United States, ahead of Eli Lilly.
• He emphasizes:
  • The Wegovy pill delivers up to 17% efficacy in weight loss if taken regularly.
  • 1 in 3 users may experience up to 20% weight loss.
• Dostar underscores the importance:
  "Christmas comes early... this is really going to be super exciting for the millions of patients that have been waiting to get their hands on a GLP1 pill." (01:21 – Mike Dostar)

2. Competing with Eli Lilly and Drug Functionality

(02:03 – 02:22)

• Katie highlights competitors, especially Eli Lilly, whose pill is set to launch two months later and may offer fewer restrictions.
• Dostar responds:
  • Emphasizes comparable efficacy between the injection and pill form.
  • Stresses >10 years of safety data backing their GLP-1.
  • Glows about the dual benefits: “Not only going to reduce your weight, it also has protection for your cardiovascular systems. So this is a phenomenal pill, second to none, I would say.” (02:22 – Mike Dostar)

3. Distribution and Sales Channels

(03:17 – 03:57)

• Dostar confirms a broad launch strategy:
  • Will sell via NovoCare Pharmacy, RO, LifeMD, Costco, Weight Watchers, TrumpRx (coming soon), and traditional pharmacies.
• Key quote:
  "Everyone that you can imagine is going to start launching this at the same time on the day of the launch." (03:27 – Mike Dostar)

4. Scaling up Supply and Overcoming Challenges

(03:57 – 05:25)

• Dostar recounts the scientific breakthrough in putting peptides in a pill, describing it as previously "impossible."
• Confident in manufacturing capacity:
  “We have shown confidence that we are able to scale this more than enough for every single person who would want to take the pill. And we are ready for that.” (04:14 – Mike Dostar)
• Asserts affordability and scalability, calling the product:
  "Borderline miracle in my own humble opinion, a peptide in a pill with a high efficacy produced at scale and we're going to actually sell it through all channels at relatively affordable price." (05:12 – Mike Dostar)

5. Market Expansion vs. Cannibalization Concerns

(05:25 – 06:29)

• Katie asks whether the pill could expand the total market or merely cannibalize injectables.
• Dostar predicts significant market growth, citing people hesitant about injections:
  "There are a number of people... they have not... taken that journey because they've been either afraid of injections or there is a taboo of injection. I think a lot of these people today will be able to find wegovy pill incredibly interesting as a way to come in." (05:42 – Mike Dostar)
• Emphasizes new patient access because of the pill format.

6. Pricing and Political Context

(06:29 – 07:23)

• Reference to pricing deals with the Trump administration.
• Dostar stresses commitment to affordability and access:
  • Starting price of $149 for oral Wegovy—asserted as accessible to many.
  • Pledges to monitor and adjust prices to maintain broad access as the market expands.
• Quote:
  "We have announced that we will start the starting dose of the begovi pill at 149, which I think is a very affordable price for many Americans to, to get interested at." (06:46 – Mike Dostar)

7. Mergers & Acquisitions and Future Strategy

(07:23 – 08:24)

• Katie probes on future acquisitions after losing a bidding war with Pfizer over Med Sarah.
• Dostar affirms active efforts to seek pipeline enhancements:
  • “We have made it very clear that we would like to sustain our leadership in diabetes and obesity and go very deep. We have a fantastic pipeline in both of those therapy areas, but the world is very large. We are dealing with some close to 2 billion people... you will continue looking not just in your own research shop but everywhere else…” (07:40 – Mike Dostar)
• Novo Nordisk’s intent: stay competitive through internal R&D and external deals.

Notable Quotes and Memorable Moments

• "Christmas comes early... this is really going to be super exciting for the millions of patients that have been waiting to get their hands on a GLP1 pill."
  — Mike Dostar, (01:21)

• "For the first time ever, people do not to have compromise between either taking an efficacious injection or a convenient pill... you have the same efficacy of 17% in injection or appeal."
  — Mike Dostar, (02:22)

• "Everyone that you can imagine is going to start launching this at the same time on the day of the launch."
  — Mike Dostar, (03:27)

• "Borderline miracle in my own humble opinion, a peptide in a pill with a high efficacy produced at scale and we're going to actually sell it through all channels at relatively affordable price."
  — Mike Dostar, (05:12)

• "I think the market will expand quite a bit actually for many of these people that have just been waiting and seeing the injectable versions of these GLP1 products. Taking, taking the world by storm."
  — Mike Dostar, (06:03)

• "We have announced that we will start the starting dose of the begovi pill at 149, which I think is a very affordable price for many Americans to, to get interested at."
  — Mike Dostar, (06:46)

• "...you will continue looking not just in your own research shop but everywhere else to see how complementary wise you could actually have the best pipeline available and the best offering amongst all your competitors."
  — Mike Dostar, (07:58)

Timestamps for Important Segments

• Novo Nordisk’s first-to-market advantage and product benefits: 00:34–02:03
• Discussion of competition, efficacy, and safety: 02:03–03:17
• Distribution plans and launch channels: 03:17–03:57
• Scaling production and technical breakthroughs: 03:57–05:25
• Market expansion and consumer hesitancy: 05:25–06:29
• Pricing and political factors: 06:29–07:23
• M&A and future innovation strategy: 07:23–08:24

Conclusion

The interview offers a revealing look into Novo Nordisk’s ambition with the Wegovy pill—bridging science, accessibility, and business strategy. Dostar’s conviction in the product’s efficacy, availability, and transformative market potential is unmistakable. The conversation explores not only commercial and technical aspects but also broader issues like access, affordability, and the ongoing role of innovation and acquisitions in healthcare. For listeners, it’s a comprehensive preview of how the oral GLP-1 category could redefine obesity treatment and competition in 2026.